Simple Organ Removal Slashes Deadliest Cancer Risk

Doctors now believe removing a woman’s fallopian tubes during another routine surgery can cut her future risk of ovarian cancer by roughly half.

Quick Take

A nationwide Swedish study found women who had their fallopian tubes removed had a 65% lower risk of ovarian cancer than women who did not.
Removing both tubes showed an even bigger drop in risk than removing just one.
Doctors call the surgery, known as opportunistic salpingectomy, quick, low-risk, and often doable during another planned operation.
Newer research suggests up to 70% of ovarian cancers may actually start in the fallopian tubes, not the ovaries.

What The Swedish Study Actually Found

Researchers led by Henrik Falconer tracked a huge group of Swedish women through national health records. They compared women who had a fallopian tube removed to women who had not. The result: women with a prior tube removal had a 65% lower risk of developing ovarian cancer later in life. That number comes from tracking real patient outcomes over years, not guesswork or lab modeling.

The protection got stronger when both tubes came out instead of just one. Bilateral removal cut ovarian cancer risk by about 50% compared to women who kept their tubes, according to the same nationwide data. Doctors at major cancer centers now point to this as one of the clearest signals yet that a simple surgical step, done during another procedure, can meaningfully change a woman’s cancer odds down the road.

Why The Fallopian Tubes Matter More Than Once Thought

For decades, doctors treated ovarian cancer as if it started in the ovaries themselves. Newer research flipped that thinking. Scientists now estimate up to 70% of ovarian cancers, especially the deadliest type, actually begin in the fallopian tubes before ever reaching the ovaries. That discovery reframed the tubes as a removable starting point for disease rather than a passive bystander.

That shift explains why removing the tubes alone, without touching the ovaries, can lower cancer risk without forcing a woman into early menopause. Keeping the ovaries preserves hormone production. Cutting the disease off at its likely starting point, the tubes, offers protection without that trade-off. Medical groups like the American College of Obstetricians and Gynecologists have pointed to this logic in encouraging surgeons to consider the procedure when patients are already having other pelvic surgery.

A Simple Add-On During Surgery Already Planned

The procedure being pushed by cancer centers is not a standalone operation. It is an add-on step, called opportunistic salpingectomy, performed while a woman is already having her uterus removed, getting sterilized, or undergoing another gynecologic surgery. Mayo Clinic doctors note it adds just a few extra minutes to an existing procedure while delivering a lasting drop in future cancer risk.

Johns Hopkins researchers have called the approach a genuine turning point in ovarian cancer prevention, noting the surgery carries low added risk for a potentially large payoff. Because ovarian cancer is often caught late and has no reliable early screening test, doctors see prevention through surgery as one of the few tools that actually moves the needle before disease ever develops.

One Study Struck A More Cautious Note

Not every dataset lines up perfectly. A later Ontario cohort study tracking over 130,000 women found no statistically significant link between salpingectomy and lower ovarian cancer rates over a seven-year follow-up period. Researchers note observational studies like these can vary based on follow-up length and which women get compared to which. That single result has not slowed the broader medical consensus favoring the procedure.

.@ABC News’ @RhiannonAlly and @drtaranarula discuss how fallopian tube removal procedure may reduce ovarian cancer risk by up to 80%. pic.twitter.com/K6LAcCyQpX

— Good Morning America (@GMA) August 10, 2026

Despite that one outlier finding, the weight of the evidence, spanning Swedish national registries, American academic hospitals, and international meta-analyses, points the same direction. Removing the fallopian tubes during an already-planned surgery looks like a low-cost, low-risk way to meaningfully lower a woman’s odds of facing one of the deadliest gynecologic cancers later in life. For women already scheduled for pelvic surgery, it is a conversation worth having with a doctor before the operating room.